α1-抗胰蛋白酶缺乏症增強療法市場：依藥物類型、給藥途徑、通路及地區分類

2026年，α1-抗胰蛋白酶缺乏症增強療法市場規模預計為18.782億美元，預計到2033年將達到24.619億美元。預計2026年至2033年，該市場將以3.94%的複合年成長率成長。

α1-抗胰蛋白酶缺乏症（AATD）是一種遺傳性疾病，其特徵是α1-抗胰蛋白酶水平不足。這種缺乏會導致肺部和肝臟進行進行性損傷，最終導致這些器官功能障礙。該疾病在全球範圍內影響約2000至5000分之一的人口。它通常與肺氣腫、慢性阻塞性肺病（COPD）和肝臟問題的發生有關。 AATD的主要治療方法是替代療法，旨在透過提高抗蛋白酶活性來保護肺部。

這種療法用於彌補蛋白質缺乏並延緩疾病進展。全球α1-抗胰蛋白酶缺乏症增強療法市場涵蓋多種產品，例如每週一次和長期製劑，以及新型生物相似藥和給藥方法。人們對這種診斷困難的疾病的認知不斷提高，以及新的診斷方法的開發，都促進了全球α1-抗胰蛋白酶缺乏症增強療法市場的成長。

市場動態

全球α1-抗胰蛋白酶缺乏症增效治療市場正快速擴張。這一成長主要得益於人們對該疾病認知的不斷提高。此外，診斷方法的進步，包括篩檢和基因檢測，也簡化了患者的識別流程。慢性阻塞性肺病（COPD）和肺氣腫等呼吸系統疾病盛行率的上升，也對市場發展起到了重要的推動作用，因為越來越多的此類患者得到了診斷和治療。

然而，該市場存在諸多障礙。其中之一是替代療法的高成本。由於每位患者每年的費用遠超過10萬美元，這種療法難以普及，也為醫療機構帶來了沉重負擔。此外，血漿提取的複雜生產流程、政府監管以及患者數量較少也是該市場面臨的其他挑戰。儘管這些障礙阻礙了市場成長，但在重組藥物和生物相似藥的研發以及皮下注射等更佳給藥途徑的開發方面，仍有許多機會。

本報告的主要特點

• 本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
• 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
• 本文檔根據以下參數，介紹了全球α-1抗胰蛋白酶缺乏症增強治療市場的主要公司概況：公司概況、產品系列、主要亮點、財務績效和策略。
• 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
• 《全球α1抗胰蛋白酶缺乏症增強療法市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過分析全球α-1抗胰蛋白酶缺乏症增強療法市場中使用的各種策略矩陣來促進決策。

目錄

第1章：分析目標與假設

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 影響分析
• 主要亮點
• 法規環境
• 產品上市及核准
• PEST分析
• 波特的分析
• 市場機遇
• 法規環境
• 主要進展
• 產業趨勢

第4章 全球α1-抗胰蛋白酶缺乏症增強療法市場：依藥物類型分類（2021-2033年）

• 格拉西亞
• 阿拉拉斯NP
• 彈性蛋白C
• 特里普森
• 澤邁拉
• 後期藥物

第5章 全球α1-抗胰蛋白酶缺乏症增強療法市場：依給藥途徑分類（2021-2033年）

• 吸入
• 注射

第6章：全球α1-抗胰蛋白酶缺乏症增強療法市場：依分銷管道分類（2021-2033年）

• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球α1-抗胰蛋白酶缺乏症增強療法市場：按地區分類（2021-2033年）

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 亞太其他地區
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第8章 競爭情勢

• Grifols SA
• CSL Behring
• Takeda Pharmaceutical Company Limited
• Kamada Ltd.
• Baxter International Inc.
• LFB Biotechnologies
• Pfizer Inc.
• AstraZeneca plc
• Arrowhead Pharmaceuticals, Inc.
• Vertex Pharmaceuticals Incorporated

第9章 分析師建議

• 機會
• 分析師意見
• Coherent Opportunity Map (COM)

第10章：參考文獻與分析方法

• 參考
• 分析方法
• 關於 Coherent Market Insights

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market is estimated to be valued at USD 1,878.2 Mn in 2026 and is expected to reach USD 2,461.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.94% from 2026 to 2033.

Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder that results in insufficient levels of alpha-1 antitrypsin protein. This deficiency leads to lung and liver dysfunction because it causes progressive damage to these organs. This health condition affects about one person out of 2,000 to 5,000 worldwide. It is usually associated with the development of emphysema, chronic obstructive pulmonary disease (COPD), and liver issues. Augmentation therapy is used as the key treatment in the management of AATD in order to provide protection to the lungs via increasing anti-protease activity.

It is used to compensate for the insufficient levels of protein and slow down the progression of disease. There is a wide variety of products in the global Alpha-1 antitrypsin deficiency augmentation therapy market including different formulations like weekly or extended administration, as well as new biosimilars and drug administration methods. The growing awareness regarding the existence of this underdiagnosed condition and the development of new approaches to its diagnosis contribute to the growth of the global Alpha-1 antitrypsin deficiency augmentation therapy market.

Market Dynamics

The global Alpha-1 antitrypsin deficiency augmentation therapy market is expanding rapidly. This growth is largely driven by increased awareness of the condition. Furthermore, advancements in diagnostic methods, including screening and genetic testing, have simplified the process of identifying more individuals with the disease. The growing incidence of respiratory diseases, like COPD and emphysema, also plays an important role in driving the market, as more patients with these diseases are diagnosed and enrolled in treatments.

However, there are a number of hurdles in this market including the expensive cost involved in the use of augmentative therapies with a cost of well over USD 100,000 annually per patient, making it tough to make this treatment available and putting health care institutions under pressure. In addition, difficult production processes involving the use of plasma, government regulations, and low number of patients form other challenges faced by this market. Even though these obstacles pose a hurdle to growth in the market, there are many opportunities in the development of recombinant or biosimilars medications and better modes of administration such as subcutaneous.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Alpha-1 antitrypsin deficiency augmentation therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Grifols S.A., CSL Behring, Takeda Pharmaceutical Company Limited, Kamada Ltd., Baxter International Inc., LFB Biotechnologies, Pfizer Inc., AstraZeneca plc, Arrowhead Pharmaceuticals, Inc., and Vertex Pharmaceuticals Incorporated
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Alpha-1 antitrypsin deficiency augmentation therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alpha-1 antitrypsin deficiency augmentation therapy market

Market Segmentation

• Drug Insights (Revenue, USD Mn, 2021 - 2033)
  • Glassia
  • Aralast NP
  • Prolastin C
  • Trypsone
  • Zemaira
  • Late Phase Drug
• Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
  • Inhalational
  • Injections
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Grifols S.A.
  • CSL Behring
  • Takeda Pharmaceutical Company Limited
  • Kamada Ltd.
  • Baxter International Inc.
  • LFB Biotechnologies
  • Pfizer Inc.
  • AstraZeneca plc
  • Arrowhead Pharmaceuticals, Inc.
  • Vertex Pharmaceuticals Incorporated

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Drug
  • Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Route of Administration
  • Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Distribution Channel
  • Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trends

4. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Drug, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Glassia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Aralast NP
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Prolastin C
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Trypsone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Zemaira
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Late Phase Drug
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Route of Administration, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Inhalational
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Injections
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Distribution Channel, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Region, 2021 - 2033, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Grifols S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• CSL Behring
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Kamada Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Baxter International Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• LFB Biotechnologies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Arrowhead Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Vertex Pharmaceuticals Incorporated
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us